Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 5 | 2023 | 134 | 2.240 |
Why?
|
| Coronary Disease | 9 | 2015 | 43 | 1.640 |
Why?
|
| Cardiovascular Diseases | 6 | 2020 | 235 | 1.450 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 37 | 1.440 |
Why?
|
| Cisplatin | 2 | 2023 | 50 | 1.380 |
Why?
|
| Cardiology | 5 | 2021 | 23 | 1.270 |
Why?
|
| Secondary Prevention | 5 | 2020 | 44 | 1.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 187 | 1.230 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 470 | 1.140 |
Why?
|
| Cardiac Rehabilitation | 4 | 2021 | 4 | 1.090 |
Why?
|
| Acrylamides | 2 | 2020 | 3 | 0.820 |
Why?
|
| Aniline Compounds | 2 | 2020 | 29 | 0.820 |
Why?
|
| Heart Failure | 7 | 2021 | 106 | 0.780 |
Why?
|
| Exercise Test | 3 | 2018 | 56 | 0.780 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 196 | 0.720 |
Why?
|
| Humans | 38 | 2023 | 22848 | 0.720 |
Why?
|
| Carboplatin | 1 | 2021 | 26 | 0.710 |
Why?
|
| Benzimidazoles | 1 | 2021 | 9 | 0.710 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2021 | 6 | 0.710 |
Why?
|
| Paclitaxel | 1 | 2021 | 48 | 0.710 |
Why?
|
| Standard of Care | 1 | 2020 | 10 | 0.700 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 7 | 0.660 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 12 | 0.640 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2018 | 4 | 0.600 |
Why?
|
| Life Style | 3 | 2019 | 127 | 0.600 |
Why?
|
| Lipocalin-2 | 1 | 2018 | 1 | 0.590 |
Why?
|
| Cystatin C | 1 | 2018 | 3 | 0.590 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 155 | 0.580 |
Why?
|
| Mutation | 1 | 2019 | 284 | 0.580 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 34 | 0.570 |
Why?
|
| Apoptosis | 2 | 2022 | 172 | 0.560 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 227 | 0.550 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2017 | 1 | 0.550 |
Why?
|
| Taxoids | 1 | 2017 | 10 | 0.550 |
Why?
|
| ErbB Receptors | 3 | 2023 | 46 | 0.520 |
Why?
|
| Cell Proliferation | 1 | 2017 | 158 | 0.520 |
Why?
|
| Aged | 19 | 2023 | 7669 | 0.500 |
Why?
|
| Neoplasms | 1 | 2018 | 205 | 0.490 |
Why?
|
| Myocardial Ischemia | 1 | 2014 | 23 | 0.450 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 108 | 0.450 |
Why?
|
| Middle Aged | 16 | 2021 | 7555 | 0.450 |
Why?
|
| Vulnerable Populations | 1 | 2013 | 20 | 0.430 |
Why?
|
| Coronary Artery Disease | 2 | 2017 | 85 | 0.430 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 31 | 0.420 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 337 | 0.410 |
Why?
|
| Acute Coronary Syndrome | 3 | 2021 | 10 | 0.400 |
Why?
|
| Male | 18 | 2023 | 12453 | 0.400 |
Why?
|
| Depression | 2 | 2015 | 375 | 0.370 |
Why?
|
| Female | 17 | 2021 | 12677 | 0.370 |
Why?
|
| Critical Pathways | 1 | 2011 | 14 | 0.360 |
Why?
|
| Program Evaluation | 3 | 2017 | 96 | 0.360 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2011 | 13 | 0.350 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 200 | 0.340 |
Why?
|
| Prognosis | 4 | 2021 | 630 | 0.340 |
Why?
|
| Chest Pain | 1 | 2009 | 12 | 0.320 |
Why?
|
| Mass Screening | 1 | 2011 | 154 | 0.320 |
Why?
|
| Models, Statistical | 1 | 2009 | 110 | 0.310 |
Why?
|
| Smartphone | 2 | 2021 | 12 | 0.310 |
Why?
|
| Australia | 8 | 2021 | 41 | 0.310 |
Why?
|
| Medication Adherence | 1 | 2009 | 33 | 0.310 |
Why?
|
| Risk Factors | 9 | 2019 | 1942 | 0.300 |
Why?
|
| Exercise Therapy | 2 | 2021 | 67 | 0.300 |
Why?
|
| Young Adult | 4 | 2021 | 1721 | 0.280 |
Why?
|
| Quality of Life | 4 | 2021 | 504 | 0.270 |
Why?
|
| Death, Sudden | 1 | 2006 | 7 | 0.260 |
Why?
|
| Adult | 7 | 2021 | 6584 | 0.230 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2018 | 39 | 0.230 |
Why?
|
| Prospective Studies | 5 | 2018 | 1528 | 0.210 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2023 | 24 | 0.210 |
Why?
|
| Cetuximab | 1 | 2023 | 6 | 0.210 |
Why?
|
| Laryngeal Neoplasms | 1 | 2023 | 32 | 0.210 |
Why?
|
| Counseling | 2 | 2017 | 39 | 0.190 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 4055 | 0.190 |
Why?
|
| Cell-Derived Microparticles | 1 | 2022 | 7 | 0.190 |
Why?
|
| Nose Neoplasms | 1 | 2022 | 40 | 0.190 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2022 | 63 | 0.190 |
Why?
|
| Risk Assessment | 3 | 2019 | 485 | 0.190 |
Why?
|
| Radiosurgery | 1 | 2021 | 33 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 155 | 0.170 |
Why?
|
| Societies, Medical | 2 | 2020 | 101 | 0.170 |
Why?
|
| Comorbidity | 4 | 2021 | 354 | 0.170 |
Why?
|
| Retrospective Studies | 5 | 2023 | 3062 | 0.170 |
Why?
|
| United Kingdom | 1 | 2019 | 42 | 0.160 |
Why?
|
| Blood Circulation | 1 | 2019 | 1 | 0.160 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 5 | 0.160 |
Why?
|
| Circulating Tumor DNA | 1 | 2019 | 6 | 0.160 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 50 | 0.160 |
Why?
|
| Treatment Outcome | 5 | 2021 | 2960 | 0.160 |
Why?
|
| Walking Speed | 1 | 2019 | 34 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 26 | 0.160 |
Why?
|
| Diastole | 1 | 2019 | 24 | 0.160 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 20 | 0.160 |
Why?
|
| Obesity, Abdominal | 1 | 2019 | 13 | 0.160 |
Why?
|
| Stroke Volume | 1 | 2019 | 27 | 0.160 |
Why?
|
| Waist Circumference | 1 | 2019 | 26 | 0.160 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 3 | 0.160 |
Why?
|
| Biomarkers | 2 | 2019 | 453 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 52 | 0.150 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 377 | 0.150 |
Why?
|
| Peptide Fragments | 1 | 2019 | 56 | 0.150 |
Why?
|
| Infection Control | 1 | 2020 | 169 | 0.150 |
Why?
|
| American Heart Association | 1 | 2018 | 11 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 71 | 0.150 |
Why?
|
| Mouth | 1 | 2018 | 12 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 75 | 0.150 |
Why?
|
| Exercise | 1 | 2021 | 305 | 0.150 |
Why?
|
| Pharynx | 1 | 2018 | 11 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 201 | 0.150 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 31 | 0.150 |
Why?
|
| Hemorrhage | 1 | 2018 | 73 | 0.150 |
Why?
|
| Aspirin | 1 | 2018 | 70 | 0.140 |
Why?
|
| Signal Transduction | 1 | 2019 | 354 | 0.140 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2017 | 4 | 0.140 |
Why?
|
| Health Behavior | 3 | 2021 | 123 | 0.140 |
Why?
|
| Coronary Vessels | 1 | 2017 | 26 | 0.140 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 177 | 0.140 |
Why?
|
| Caspases | 1 | 2017 | 22 | 0.140 |
Why?
|
| United States | 3 | 2018 | 1726 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 115 | 0.130 |
Why?
|
| Blotting, Western | 1 | 2017 | 130 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2019 | 400 | 0.130 |
Why?
|
| Telephone | 2 | 2014 | 22 | 0.130 |
Why?
|
| Patient Compliance | 3 | 2016 | 117 | 0.120 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 165 | 0.120 |
Why?
|
| Depressive Disorder | 2 | 2015 | 121 | 0.110 |
Why?
|
| Calcium | 1 | 2017 | 333 | 0.110 |
Why?
|
| New Zealand | 3 | 2020 | 11 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2011 | 149 | 0.090 |
Why?
|
| Affect | 1 | 2011 | 53 | 0.090 |
Why?
|
| Family Practice | 1 | 2009 | 14 | 0.080 |
Why?
|
| Bayes Theorem | 1 | 2009 | 34 | 0.080 |
Why?
|
| Medical Audit | 1 | 2009 | 5 | 0.080 |
Why?
|
| Telemedicine | 1 | 2011 | 79 | 0.080 |
Why?
|
| Unnecessary Procedures | 1 | 2009 | 21 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 29 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2009 | 16 | 0.080 |
Why?
|
| Electrocardiography | 1 | 2009 | 70 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2009 | 19 | 0.080 |
Why?
|
| Program Development | 1 | 2009 | 42 | 0.080 |
Why?
|
| Exercise Tolerance | 2 | 2021 | 13 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 43 | 0.080 |
Why?
|
| Prevalence | 1 | 2009 | 377 | 0.070 |
Why?
|
| Incidence | 2 | 2019 | 649 | 0.070 |
Why?
|
| Myocardial Revascularization | 1 | 2006 | 8 | 0.070 |
Why?
|
| Life Expectancy | 1 | 2006 | 26 | 0.060 |
Why?
|
| Time Factors | 1 | 2009 | 1220 | 0.060 |
Why?
|
| Survival Rate | 1 | 2006 | 270 | 0.060 |
Why?
|
| Cholesterol | 2 | 2003 | 59 | 0.060 |
Why?
|
| Hypercholesterolemia | 2 | 2002 | 21 | 0.060 |
Why?
|
| Printing, Three-Dimensional | 1 | 2023 | 8 | 0.050 |
Why?
|
| Immobilization | 1 | 2023 | 13 | 0.050 |
Why?
|
| Laryngectomy | 1 | 2023 | 19 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 30 | 0.050 |
Why?
|
| Neck | 1 | 2023 | 24 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2023 | 28 | 0.050 |
Why?
|
| Patient-Centered Care | 1 | 2003 | 39 | 0.050 |
Why?
|
| Chemoradiotherapy | 1 | 2023 | 55 | 0.050 |
Why?
|
| Victoria | 2 | 2019 | 8 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 36 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 6 | 0.050 |
Why?
|
| Anticholesteremic Agents | 1 | 2002 | 13 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2021 | 3 | 0.050 |
Why?
|
| Length of Stay | 1 | 2023 | 279 | 0.050 |
Why?
|
| Walk Test | 1 | 2021 | 9 | 0.050 |
Why?
|
| Early Medical Intervention | 1 | 2021 | 9 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 175 | 0.050 |
Why?
|
| Health Promotion | 1 | 2002 | 100 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 334 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2021 | 260 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 82 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 16 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 61 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 588 | 0.040 |
Why?
|
| Echocardiography | 1 | 2019 | 54 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 129 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 121 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 82 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2018 | 138 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 381 | 0.040 |
Why?
|
| Propensity Score | 1 | 2017 | 30 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2017 | 18 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2018 | 295 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2019 | 172 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 104 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 210 | 0.030 |
Why?
|
| Disease Management | 1 | 2017 | 82 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 657 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 67 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 1494 | 0.030 |
Why?
|
| Text Messaging | 1 | 2016 | 8 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 85 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 685 | 0.030 |
Why?
|
| Independent Living | 1 | 2018 | 265 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 500 | 0.030 |
Why?
|
| Anxiety | 1 | 2015 | 107 | 0.030 |
Why?
|
| Social Support | 1 | 2015 | 156 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 1621 | 0.030 |
Why?
|
| Hypolipidemic Agents | 2 | 2003 | 16 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2011 | 25 | 0.020 |
Why?
|
| Cardiovascular Agents | 1 | 2011 | 18 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2011 | 51 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 157 | 0.020 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2006 | 16 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2006 | 22 | 0.020 |
Why?
|
| Aftercare | 1 | 2006 | 20 | 0.020 |
Why?
|
| Physical Examination | 1 | 2006 | 105 | 0.020 |
Why?
|
| Palliative Care | 1 | 2006 | 94 | 0.020 |
Why?
|
| Allied Health Personnel | 1 | 2003 | 7 | 0.010 |
Why?
|
| Nursing Staff, Hospital | 1 | 2003 | 21 | 0.010 |
Why?
|
| Europe | 1 | 2002 | 50 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 110 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 208 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 274 | 0.010 |
Why?
|
| Hypertension | 1 | 2002 | 156 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2002 | 135 | 0.010 |
Why?
|
| Obesity | 1 | 2002 | 263 | 0.010 |
Why?
|